CN100562323C

CN100562323C - A kind of pharmaceutical composition for the treatment of hysteromyoma and preparation method thereof

Info

Publication number: CN100562323C
Application number: CNB2005100887181A
Authority: CN
Inventors: 黄文峰
Original assignee: BEIJING LIBOYUAN MEDICINE INST
Current assignee: BEIJING LIBOYUAN MEDICINE INST
Priority date: 2005-07-29
Filing date: 2005-07-29
Publication date: 2009-11-25
Anticipated expiration: 2025-07-29
Also published as: CN1726928A

Abstract

The invention discloses a kind of pharmaceutical composition and preparation thereof for the treatment of hysteromyoma, this pharmaceutical composition is to be made by following bulk drugs: Carapax Trionycis 600-900 weight portion, Fructus Polygoni Orientalis 600-900 weight portion, rhizoma sparganic 400-600 weight portion or add Herba Scutellariae Barbatae 600-900 weight portion, Semen Coicis 600-900 weight portion, Radix Notoginseng 250-350 weight portion again.The preparation method of said composition is earlier with Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis alcohol extraction, and the alcohol extraction medicinal residues are standby, and filtrate decompression is condensed into clear paste I; Carapax Trionycis decocts with water 1 hour, adds the alcohol extraction medicinal residues again, and water is carried, and merges the water extract, leaves standstill, and filters, and filtrate decompression concentrates clear paste II, and is standby; With clear paste I, clear paste II and Radix Notoginseng micropowder mix homogeneously, drying gets dry extract, and adds conventional adjuvant, is prepared into clinical acceptable various dosage forms.The present invention also provides the method for quality control and the pharmaceutical applications of this pharmaceutical composition tablet.

Description

A kind of pharmaceutical composition for the treatment of hysteromyoma and preparation method thereof

Technical field

The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of hysteromyoma and preparation method thereof and method of quality control.

Background technology

Hysteromyoma system is formed by uterine smooth muscle and connective tissue proliferation, claims leiomyoma of uterus again, is modal benign tumor in the female sex organ.Difference by position, muscular tumor place can be divided into myoma corporis uteri and myoma of cervix uteri, and the former accounts for hysteromyoma 90～96%, and the latter only accounts for 2.2～8%.Simultaneously, the relation according to muscular tumor and uterine muscular is divided three classes it: intramural myoma, Subserous myoma, fleshy polyp.The clinical manifestation of hysteromyoma is different and different with growth site, size, the speed of growth and the complication etc. of muscular tumor often.The patient who has is also asymptomatic clinically, and what have then has a metrorrhagia, abdominal mass, and pain, the adjacent organs pressure symptom, leucorrhoea grow in quantity, infertile, secondary anemia etc.

Current, there are three big difficult points in hysteromyoma in morbidity and treatment:

One, sickness rate height.Hysteromyoma is more common in 30～50 years old women, and wherein 40～50 years old women's incidence rate is up to 51.2～60%, and 1988～nineteen ninety, hysteromyoma occupied the 5th in the U.S. women of child-bearing age are in hospital because of gynaecopathia.Though clinical statistics muscular tumor incidence rate does not have definite data in China, there is data to show that its incidence rate was in rising trend in the last few years.As seen should disease become the able-bodied main disease of harm women.

Two, treatment difficulty.Not outer Drug therapy of the existing Therapeutic Method of hysteromyoma and operative treatment.Because this disease is the sex hormone dependent benign tumor, the treatment of many clinically employing hormonal medicaments lasts nearly half a century, multiple medicine once on probation, but the medicine of radical cure muscular tumor still is in heuristic process.Though there have new drug to be applied to successively in the recent period to be clinical, curative effect increases, but the side effect of hormonal medicaments can not be ignored.Operative therapy is a simple but effective method, often is unwilling again to accept for most of women, and especially concerning the patient of unmarried or married unpregnancy, this kind therapy is suitable with regard to non-institute.Therefore, the academic characteristics of performance Chinese medicine, integrally-regulated and local inhibition muscular tumor combines, and reaches and can remove patient's slight illness, again the purpose that can improve the quality of living.

Three, patient's condition is touching.The formation of muscular tumor, non-one day disease, its morbidity is many by gradually and very, and year prolonged illness is dark, and day long-pending month is poly-, and knot forms tumor.About the origin of hysteromyoma with what promote that the mechanism of their growths still understands is not a lot.Think that at present conversion process that myometrial somatic cell forms to muscular tumor may relate to complex interactions between the somatic mutation of normal uterus flesh layer and the gonadal hormone and the local growth factor.Gonadal hormone comprises estrogen and progestogen, and is permitted the regulatory factor that peptide growth factor (comprising epithelium growth factor) is regarded as the muscular tumor growth.The process of muscular tumor growth is that complicated this just becomes the touching characteristics of this disease patient's condition and secular, and the treatment primary disease wants short-term response or tries to achieve the non-easy thing of quick-acting realities.

In sum,, avoid or reduce the side effect of hormone medicine, and the hardship that makes the part patient exempt operation, demand urgently clinically developing having and to carry out integrally-regulatedly, can locally suppress muscular tumor, Chinese medicine medicine safely and effectively again for increasing treatment means.

Summary of the invention

The object of the invention is to provide a kind of new pharmaceutical composition and preparation thereof, the present invention also aims to provide the preparation method of this pharmaceutical composition and preparation thereof, the object of the invention also is to provide the method for quality control of this drug combination preparation, and the object of the invention also is to provide the pharmaceutical applications of this pharmaceutical composition.

The present invention seeks to be achieved through the following technical solutions.

Pharmaceutical composition of the present invention is to be made by following bulk drugs:

Carapax Trionycis 600-900 weight portion, Fructus Polygoni Orientalis 600-900 weight portion, rhizoma sparganic 400-600 weight portion.

The crude drug optimum ratio of the invention described above pharmaceutical composition is:

Carapax Trionycis 750 weight portions, Fructus Polygoni Orientalis 750 weight portions, rhizoma sparganic 500 weight portions.

Carapax Trionycis 700 weight portions, Fructus Polygoni Orientalis 850 weight portions, rhizoma sparganic 450 weight portions.

Carapax Trionycis 850 weight portions, Fructus Polygoni Orientalis 700 weight portions, rhizoma sparganic 550 weight portions.

Get the invention described above pharmaceutical composition crude drug, press the pharmaceutics common process, add conventional adjuvant such as filler, disintegrating agent, adhesive, lubricant etc., can be prepared into clinical acceptable any dosage form, include but not limited to following dosage form: decoction, tablet, pill, powder, granule, oral liquid, decoction, injection, capsule or suspensoid.

Pharmaceutical composition of the present invention also can be made by following bulk drugs:

Carapax Trionycis 600-900 weight portion, Fructus Polygoni Orientalis 600-900 weight portion, rhizoma sparganic 400-600 weight portion, Herba Scutellariae Barbatae 600-900 weight portion, Semen Coicis 600-900 weight portion, Radix Notoginseng 250-350 weight portion.

Carapax Trionycis 750 weight portions, Fructus Polygoni Orientalis 750 weight portions, rhizoma sparganic 500 weight portions, Herba Scutellariae Barbatae 750 weight portions, Semen Coicis 750 weight portions, Radix Notoginseng 300 weight portions.

Carapax Trionycis 700 weight portions, Fructus Polygoni Orientalis 850 weight portions, rhizoma sparganic 450 weight portions, Herba Scutellariae Barbatae 850 weight portions, Semen Coicis 700 weight portions, Radix Notoginseng 320 weight portions.

Carapax Trionycis 850 weight portions, Fructus Polygoni Orientalis 700 weight portions, rhizoma sparganic 550 weight portions, Herba Scutellariae Barbatae 700 weight portions, Semen Coicis 850 weight portions, Radix Notoginseng 280 weight portions.

Carapax Trionycis can be a Carapax Trionycis (processed with vinegar) in the above-mentioned raw materials medicine, and Radix Notoginseng can be the micropowder of Radix Notoginseng.

Get the invention described above pharmaceutical composition crude drug, press the pharmaceutics common process, add conventional adjuvant such as filler, disintegrating agent, adhesive, lubricant etc., can be prepared into clinical acceptable any dosage form, include but not limited to following dosage form: decoction, tablet, pill, powder, granule, decoction, capsule or suspensoid.

Preparation of drug combination technology of the present invention is:

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis or Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 6-10 and doubly measure 70%-90% ethanol, reflux, extract, 1-3 time, each 1-2 hour, extracting solution merges, and leaves standstill, and filters, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis or Carapax Trionycis (processed with vinegar) decoct with water 1 hour, add the alcohol extraction medicinal residues again, add the water that 8-12 doubly measures, and decoct 1-3 time, each 0.5-1.5 hour, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

Radix Notoginseng powder is broken into 80 purpose coarse powder, then the coarse powder superfine powder is broken into micropowder, or directly get the Radix Notoginseng micropowder, standby;

With clear paste I, clear paste II and Radix Notoginseng micropowder mix homogeneously, put the vacuum drying oven drying, temperature is not higher than 80 ℃, gets dry extract, and pharmaceutical composition extract promptly of the present invention is standby;

Get pharmaceutical composition extract of the present invention, add conventional adjuvant such as filler, disintegrating agent, adhesive, lubricant etc., according to the pharmaceutics common process, be prepared into clinical acceptable any dosage form, include but not limited to tablet, capsule, granule, pill or granule.

In the invention described above preparation of pharmaceutical compositions method, the Radix Notoginseng micropowder can be the micropowder of particle diameter≤20 μ m or the micropowder that Radix Notoginseng coarse powder micronizing becomes particle diameter≤20 μ m.

Pharmaceutical composition of the present invention can add adjuvants such as filler, disintegrating agent, adhesive, lubricant and make tablet on the basis of above-mentioned weight portion crude drug.Tablet of the present invention can be by following prepared:

With clear paste I, clear paste II and Radix Notoginseng micropowder mix homogeneously, put the vacuum drying oven drying, temperature is not higher than 80 ℃, gets dry extract, and is standby;

Dried cream powder is broken, sieve, adding weight ratio is the lactose of 15-30%, with the weight ratio is that 8-12%, concentration are that the poly-iodine ketone K30 alcoholic solution of 5-15% is made soft material, granulates drying, granulate adds 1-3% cross-linking sodium carboxymethyl cellulose and 0.5-1% magnesium stearate, mix homogeneously; Tabletting, sheet heavily are 0.87g; With Opadry thin film coating material coating, coating is to the heavy 0.90g of sheet; Plastic bottle packing is distributed into 60 slices/bottle, promptly.

In the invention described above method for preparing tablet thereof, the Radix Notoginseng micropowder can be the micropowder of particle diameter≤20 μ m or the micropowder that Radix Notoginseng coarse powder micronizing becomes particle diameter≤20 μ m; Soft material can be granulated and granulate with 14 order stainless steel meshs, and baking temperature is not higher than 60 ℃.

The method of quality control of pharmaceutical composition tablet of the present invention comprises one or more in following discriminating and/or the content assaying method:

Differentiate: A. gets tablet 1g of the present invention, and porphyrize adds 10 in water, stir evenly water-saturated n-butanol solution 10ml in addition again, close plug, about 10 minutes of jolting was placed 2 hours, and is centrifugal, get supernatant, add 3 times of saturated aqueous solutions of amount n-butyl alcohol, shake up, placement makes layering, gets n-butyl alcohol liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets Radix Notoginseng control medicinal material 0.5g, shines medical material solution in pairs with legal system; It is an amount of to get the arasaponin R1 reference substance again, adds methanol and makes the reference substance solution that every 1ml contains 0.5mg; Test according to thin layer chromatography (appendix IV B), draw each 1 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, be that lower floor's solution that chloroform-ethyl acetate-methanol-water of 12-18: 32-48: 18-26: 8-12 is placed below 10 ℃ is developing solvent with the ratio, launch, take out, dry, spray to be being diluted to 1ml the ethanol solution of sulfuric acid of 10ml, and it is clear to be heated to the speckle colour developing in 105 ℃; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance chromatograph on, show the speckle of same color;

B. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Semen Coicis control medicinal material 0.5g, gets control medicinal material solution with legal system; Test according to thin layer chromatography (appendix IV B), draw each 1 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be 8-10: 1-2 with the ratio: 0.5 30-60 ℃ petroleum ether-ether-glacial acetic acid is developing solvent, launches, take out, dry, put under the 365nm uviol lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;

C. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Herba Scutellariae Barbatae control medicinal material 0.5g, gets control medicinal material solution with legal system; It is an amount of to get the scutellarin reference substance again, adds methanol and makes the reference substance solution that every 1ml contains 1mg; Test according to thin layer chromatography (appendix IV B), draw each 5 μ l of above-mentioned solution, putting in the same carboxymethylcellulose sodium solution that contains 4% sodium acetate respectively is on the silica gel g thin-layer plate of adhesive, ethyl acetate-butanone-formic acid-the water that with the ratio is 4-6: 2-4: 1-2: 1-2 is developing solvent, presaturation 20 minutes launches, and takes out, dry, spray is with 5% ferric chloride alcoholic solution; With the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance on, show identical dirty-green speckle;

Assay: the photograph high performance liquid chromatography (" an appendix VI of Chinese pharmacopoeia version in 2005 D) measure;

Chromatographic condition and system suitability are filler with octadecylsilane chemically bonded silica; Methanol-water-the acetic acid that with the ratio is 30-40: 67-55: 3-5 is mobile phase; The detection wavelength is 335nm; Number of theoretical plate calculates by the scutellarin peak should be not less than 3000;

The preparation of reference substance solution: it is an amount of to get the scutellarin reference substance, and accurate the title decides, and adds methanol and makes the reference substance solution that every 1ml contains 80 μ g;

The preparation of need testing solution: get 20 of this films, remove coating, the accurate title, decided porphyrize, get 0.5g, the accurate title, decide, and puts in the tool plug conical flask, the accurate methanol 25ml that adds, close plug claims to decide weight, supersound process 30 minutes, ultrasonic power are that 300W, supersonic frequency are 33kHz, put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, get subsequent filtrate, promptly;

Algoscopy: accurate respectively reference substance solution and each 5ul of need testing solution of drawing, inject chromatograph of liquid, measure, promptly;

Every in tablet of the present invention contains Herba Scutellariae Barbatae with scutellarin (C ₂₁H ₁₈O ₁₂) calculate, must not be less than 1.38mg.

Hysteromyoma belongs to Chinese medicine “ mass in the abdomen with regard to its clinical manifestation lid " in " stony mass of uterus " category, pathogenesis mainly is blood stasis expectorant knot, has resembling of strongly fragrant and heat-transformation concurrently.Sincerely keep the principle of " hard masses should be resolved gradually, diseases with invaded pathogens should be treated by expelling, disease caused by accumulations of pathogen should be treated with therapy of dispersion, disease with retention of pathogen in the body should be treated by elimination therapy " in the treatment, determine hard masses softening and resolving, Hua Yu Xiao Disorder, the double method of executing clearing away heat to stop bleeding.

We are monarch drug with the Carapax Trionycis.Lid Carapax Trionycis nature and flavor are salty-cold, but both nourishing YIN for suppressing the hyperactive YANG of its effect is arrogated to oneself hard masses softening and resolving again.Because the pathogenesis key of primary disease is to stop in the blood stasis, due to expectorant stasis of blood knot is poly-, control when the blood stasis dispelling expectorant.Effect that can Qu Xiao Disorder eliminating stagnation is so be ministerial drug with Fructus Polygoni Orientalis, rhizoma sparganic in the side.Fructus Polygoni Orientalis has the activating blood circulation and dissipating blood stasis softening the hard mass to attack long-pending function, all right " following aqueous vapor ".And the rhizoma sparganic pungent drugs can disperse and bitter drugs can purge, the removing blood stasis also power of the stasis of blood is quite male, again can circulation of qi promoting, so stagnation of QI and blood is with the passing of time, amass Yi Cheng lumps in the chest and abdomen in body, and whenever rely on and be key medicine.Fructus Polygoni Orientalis, rhizoma sparganic two medicines phase 5 are total to principal drug assistance Yu Xiao Disorder, hard masses softening and resolving.

For strengthening we's drug effect, also can help in the side with Semen Coicis, Herba Scutellariae Barbatae and Radix Notoginseng.Semen Coicis is light to ooze sweet benefit, goes into the spleen kidney channel, can promoting diuresis to eliminate damp pathogen, and Qinghua expectorant knot again can the spleen invigorating invigorating middle warmer, turns round and look at and protects healthy energy.But the Herba Scutellariae Barbatae promoting blood circulation to remove blood stasis, with Zhu Xiao Disorder eliminating stagnation, but cooling blood for hemostasis again is many to palace tumor amount of bleeding, has haemostatic effect preferably.Two medicines are the adjuvant drug in the side of being altogether.Radix Notoginseng sweetness and bitterness, warm in nature, kind hemostasis dissipating blood stasis is used for various internal and external haemorrhage diseases, especially there to be stasis of blood person to be advisable; Have hemostasis and do not stay the stasis of blood, blood stasis dispelling and do not hinder positive characteristics is the sage product of mass formed by blood stasis, so be making of all medicines in fact.Full side collection vital energy regualting and blood circulation-promoting, dampness removing reduce phlegm, hard masses softening and resolving, all methods of clearing away heat to stop bleeding are melted and be one, are detained because of blood stasis with the Ji, and expectorant stasis of blood knot is poly-, or have strongly fragrant and hysteromyoma heat-transformation sign is obtained good effect.

And pharmacodynamics test shows that the present composition and various preparation thereof have the obvious suppression effect to the animal uterus muscular tumor.Tablet of the present invention can obviously suppress rat and Cavia porcellus hysteromyoma sample hypertrophy, and safety non-toxic.That tablet of the present invention can also obviously reduce is female in rat and the guinea pig serum, progesterone level and rat experiment temper palace muscular tumor smooth muscle cell ER, PR positive expression.

The high performance liquid chromatography that the present invention selects for use is that the assay of scutellarin in the sheet has been set up a kind of separation efficiency height, good stability, the fast method of analysis speed, adopts discriminating of the present invention and content assaying method to provide reliable method for the control quality of the pharmaceutical preparations.

Following experimental example and embodiment are used to further specify but are not limited to the present invention.

Experimental example 1: superfine notoginseng powder is broken

The micronizing of Radix Notoginseng, we adopt the secondary comminuting method, at first with Universalpulverizer Radix Notoginseng powder are broken into 80 purpose coarse powder, carry out micronizing then, micropowder detects through scanning electron microscope, X-ray energy spectrometer, and particle diameter≤5 μ, normal distribution are determined as 99.47%≤20 μ m.

The medicinal super micron mill micronizing of micronizing equipment: TC20 technological parameter: air pressure＞0.65Mpa; 0～5 ℃ of air pressure dew point; Air capacity 3M3/ minute; Feed size 80 orders; Charging rate 100 gram/minute; Grader frequency setting 45Hz.

Experimental example 2: the preferred research of alcohol extraction condition

Adopt Orthogonal Experiment and Design screening alcohol extraction condition: Fructus Polygoni Orientalis, Herba Scutellariae Barbatae, rhizoma sparganic and Semen Coicis four Chinese medicine material adopt the method for alcohol extraction, and medicinal residues merge water with Carapax Trionycis again and carry.Now investigate solvent doubly amount, extraction time, concentration of alcohol, the influence of four factors of extraction time to extracting, the factor level table sees the following form; Select for use total flavones amount (mg) and extractum amount (g) for investigating index, orthogonal test has been carried out data analysis, result of the test shows: best alcohol extraction process condition is 10 times of amounts of 70% ethanol, extracts 3 times, each 1.5 hours.

The quadrature factor level table of table 1. alcohol extraction condition

Experimental example 3: water is carried the optimization experiment of condition

Adopt Orthogonal Experiment and Design screening water to put forward condition, get alcohol extraction medicinal residues and Carapax Trionycis, extract by following factor level table, the factor level table sees Table 2.Reach to such an extent that the cream amount serves as to investigate index with the total polysaccharides amount, orthogonal test has been carried out data analysis, result of the test shows: best extraction process by water condition is 12 times of water gagings, extracts each 1.5 hours 3 times.

Table 2. water is carried the quadrature factor level table of condition

Experimental example 4: concentrate optimization experiment with drying condition

Suitability for industrialized production need be carried out preferably the concentration technology condition of medicinal liquid for convenience.In concentration process, concentrated solution should be controlled at certain relative density, relative density is low excessively, can influence the exsiccant time, increases production cost or medicinal liquid is taken away by vacuum; Relative density is too high, can influence the loose degree of dried cream, even can cause picking up the phenomenon of pot and gelatinizing.For the relative density that obtains suiting, and blended even, be controlled at identical relative density scope through testing the clear paste of determining alcohol extraction and water extract-alcohol precipitation, i.e. relative density 1.25-1.30 (60 ℃).In order to improve dry rate, with clear paste I, clear paste II and Radix Notoginseng micropowder mix homogeneously ,≤80 ℃ of vacuum dryings.

Experimental example 5: tablet Study on Forming of the present invention

(1) tablet molding research:

1, prescription determines

Screening by prescription adds disintegration and the unilateral fineness that magnesium stearate and cross-linking sodium carboxymethyl cellulose not only can improve particulate flowability and can improve tablet, takes all factors into consideration and determines that preparation prescription is as follows:

1. extract powder (being equivalent to medical material 3800g) 595g writes out a prescription

Lactose is an amount of

Cross-linking sodium carboxymethyl cellulose 3%

Magnesium stearate 0.5%

15% poly-iodine ketone K30 alcoholic solution is an amount of

Make 1000

2. method for making: get extractum and pulverize, cross 100 mesh sieves, add the lactose mix homogeneously with Universalpulverizer, make soft material in right amount with 15% poly-iodine ketone K30 alcoholic solution, 14 order stainless steel sifts are granulated ,≤60 ℃ of dryings, add magnesium stearate and cross-linking sodium carboxymethyl cellulose, mix homogeneously, 14 mesh sieve granulate.With special-shaped punch die tabletting, the heavy 0.87g of sheet, promptly.

2, the checking of preparation prescription

In order further to verify The selection result, carry out demonstration test by above-mentioned prescription, the results are shown in Table 3.

Three batches of preparation confirmatory experiments of table 3. result

(2) film coating research

Select the green full water thin film coating material of 85G61131 of Shanghai Ka Lekang coating material company limited for use, film coating weightening finish about 4%, the heavy 0.9g of finished product sheet carries out film coating, and technological parameter sees Table 4.

Table 4. film coating procedure parameter list

Experimental example 6: the thin layer of Radix Notoginseng is differentiated in the tablet of the present invention

In tablet of the present invention, be contrast with Radix Notoginseng control medicinal material and arasaponin R1 reference substance, adopt the TLC method that Radix Notoginseng is differentiated.The result shows: in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance chromatograph on, show the speckle of same color; And negative preparation is at corresponding position non interference composition.So list description technical scheme quality standard in.

The preparation of need testing solution: get this product 1g, porphyrize adds about 10 of water, stir evenly water-saturated n-butanol solution 5ml in addition again, close plug, about 10 minutes of jolting was placed 2 hours, and is centrifugal, get supernatant, add 3 times of saturated aqueous solutions of amount n-butyl alcohol, shake up, placement makes layering, gets n-butyl alcohol liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, promptly.

The preparation of control medicinal material solution: get Radix Notoginseng control medicinal material 0.5g, make with method by the preparation method of need testing solution.

The preparation of reference substance solution: get the arasaponin R1 reference substance, add methanol and make the solution that every 1ml contains 0.5mg.

The preparation of negative solution: get the prescription medical material that lacks Radix Notoginseng, make negative sample, make negative solution by " need testing solution preparation method " again according to the technical scheme method.

Lamellae: on the silica gel g thin-layer plate

Point sample amount: each 1ul

Developing solvent: chloroform-ethyl acetate-methanol-water (15: 40: 22: 10) lower floor's solution of placing below 10 ℃

Developer: spray is with sulfuric acid solution (1 → 10), and it is clear to be heated to speckle colour developing in 105 ℃.

The result: in the test sample chromatograph, with the corresponding position of control medicinal material on show the speckle of same color, with the speckle that shows same color on the relevant position of arasaponin R1 reference substance.And negative preparation non interference composition.

Experimental example 7: the thin layer of Semen Coicis is differentiated in the tablet of the present invention

In tablet of the present invention, be contrast with the Semen Coicis control medicinal material, adopt TLC that Semen Coicis is differentiated.The result shows: in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color; And negative preparation is at corresponding position non interference composition.So list description technical scheme quality standard in.

The preparation of need testing solution: get this product 1g, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, promptly.

The preparation of control medicinal material solution: get Semen Coicis control medicinal material 0.5g, get control medicinal material solution with legal system.

The preparation of negative solution: get the prescription medical material that lacks Semen Coicis, make negative sample, make negative solution by " need testing solution preparation method " again according to the technical scheme method.

Lamellae: silica gel G

Point sample amount: each 1 μ l

Developing solvent: petroleum ether (30-60 ℃)-ether-glacial acetic acid (9: 1: 0.5)

Inspection method: inspect under the uviol lamp (365nm),

The result: in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color, negative preparation non interference composition.Rf value is moderate.

Experimental example 8: the thin layer of Herba Scutellariae Barbatae is differentiated in the tablet of the present invention

In tablet of the present invention, be contrast with the Herba Scutellariae Barbatae control medicinal material, adopt TLC that Semen Coicis is differentiated.The result shows: in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color; And negative preparation is at corresponding position non interference composition.So list description technical scheme quality standard in.

The preparation of need testing solution: get this product 1g, porphyrize adds ethanol 10ml, and ultrasonic 30 minutes, filter, the filtrate evaporate to dryness, 1ml makes dissolving with methanol, promptly.

The preparation of control medicinal material solution: get Herba Scutellariae Barbatae control medicinal material 0.5g, get control medicinal material solution with legal system.

The preparation of negative solution: get the prescription medical material that lacks Herba Scutellariae Barbatae, make negative sample, make negative solution by " need testing solution preparation method " again according to the technical scheme method.

Each 1 μ l of point sample amount,

Lamellae: the carboxymethylcellulose sodium solution that contains 4% sodium acetate is the silica gel g thin-layer plate of adhesive

Developing solvent: ethyl acetate-butanone-formic acid-water (5: 3: 1: 1), presaturation 20 minutes

Developer: spray is with 5% ferric chloride alcoholic solution.

The result: with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance on, show identical dirty-green speckle, negative noiseless.

Experimental example 9: tablet Herba Scutellariae Barbatae content assaying method of the present invention is learned research

Herba Scutellariae Barbatae is a monarch drug in the prescription, and wherein scutellarin is its main active.Be the control quality of the pharmaceutical preparations, therefore selecting scutellarin for use is the index components of assay.We select high performance liquid chromatography for use is that the assay of scutellarin in the sheet has been set up a kind of separation efficiency height, good stability, the fast method of analysis speed, for the control quality of the pharmaceutical preparations provides reliable method.

(1) instrument and reagent

SHIMADZU high performance liquid chromatograph: LC-10AD _VPSolvent pump, SHIMADZU SPD-M10AVP diode array detector, SHIMADZU SCL10AVP controller, LCMS solution 2.04 work stations (Shimadzu Seisakusho Ltd.)

The scutellarin reference substance: Nat'l Pharmaceutical ﹠ Biological Products Control Institute, for assay usefulness, lot number: 880-200001.

Tablet of the present invention: Nanjing Zhongshan Pharmaceutical Factory lot number: 031201,031202,031203

Methanol is chromatographically pure; Water is redistilled water; Other reagent is analytical pure.

(2) chromatographic condition

Chromatographic column: the Lichrospher C18Pro.No 1C18254F Media 10nm 5 μ m Ser.No04130419Column 4.6 * 250mm of Chinese nation

Column temperature: 30 ℃

Mobile phase: methanol-water-acetic acid (35: 61: 4)

Flow velocity: 1ml/min

Detect wavelength: 335nm

Scutellarin and other component reach baseline separation under this condition.

(3) preparation of reference substance stock solution

Precision takes by weighing scutellarin reference substance 25mg respectively, puts in the 25ml volumetric flask, adds dissolve with methanol and is diluted to scale, shakes up promptly.

(4) reference substance purity testing

Get the about 10mg of scutellarin, the accurate title, decide, and puts in the 10ml measuring bottle, adds methanol to scale, shakes up, and gets the test liquid of high concentration.The above-mentioned solution 1ml of accurate absorption puts in the 50ml measuring bottle, adds methanol to scale, shakes up, and gets contrast solution.Draw test liquid, contrast solution injection chromatograph of liquid, quantitatively encircle sample introduction (5 μ l), measure reference substance purity.

Reference substance purity is 98.33%

(5) preparation of need testing solution

Get 20 of this films and remove coating, the accurate title, decide, and porphyrize is got 0.5g, and it is fixed to put accurate title, puts in the tool plug conical flask, the accurate methanol 25ml that adds claims decide weight, and ultrasonic 30 minutes, put coldly, weight decided in title again, supply the weight that subtracts mistake with methanol, shake up, filter, get subsequent filtrate, promptly.

(6) assay method

Accurate respectively reference substance solution and each 5 μ l of need testing solution of drawing inject chromatograph of liquid, measure by above chromatographic condition, and be vertical coordinate with the peak area, with the sample size abscissa, calculate content with the external standard two-point method.

(7) mensuration of negative sample

Get the about 0.5g of negative sample (not containing Herba Scutellariae Barbatae), precision claims fixed, prepares by method under " preparation of test sample test solution " item in accordance with the law, and sample introduction 5 μ l measure by above-mentioned chromatographic condition.By collection of illustrative plates is to locate not have absworption peak in 13.8 minutes to occur in retention time as can be known.

(8) drafting of standard curve

Accurate absorption reference substance stock solution (1.001mg/ml) is an amount of respectively, is diluted to 20.02 μ g/ml with methanol, 40.04 μ g/ml, 60.06 μ g/ml, 80.08 μ g/ml, 100.10 μ g/ml, the reference substance solution of 120.12 μ g/ml.Each sample introduction 5 μ l measures peak area by above-mentioned chromatographic condition, is vertical coordinate with the peak area integrated value, and reference substance concentration is abscissa drawing standard curve, calculates regression equation.Regression equation: Y=18876X (μ g/ml)-80865 (correlation coefficient r=0.9996, n=6).

Table 5 standard curve determination tables of data

The result shows that scutellarin is linear in 0.1001-0.6006 μ g scope.

(9) stability test

Get tablet of the present invention (lot number: 031201) 20, remove coating, accurate claim surely, porphyrize is got about 0.5g, the accurate title, decide, prepare by method under " preparation of need testing solution " item, sample introduction 5 μ l exist respectively in accordance with the law, and 0,2,4,8, the 12h sample introduction amounts to sample introduction 5 times, measures its stability.Statistical result shows that the RSD of response value (A) is 1.00%, shows that sample solution is stable in 12 hours.The results are shown in Table 6.

Table 6 stability test tables of data

(10) precision test

The accurate reference substance solution 5 μ l that draw 60.06g/ml, continuous sample introduction 6 times calculates average peak area value and RSD (%).The results are shown in Table 7.

Table 7 Precision test result

(11) repeatability test

Get tablet of the present invention (lot number: 031201) 5 parts of each 0.5g, accurate claim fixed, by " preparation of need testing solution " down method prepare every part of sample introduction 2 times, sample introduction 5 μ l in accordance with the law.The results are shown in Table 8.

Table 8 repeatability test data table

(12) recovery test: application of sample absorption method

Get tablet of the present invention (lot number: 031201) 0.25g, the accurate title, decide, add a certain amount of scutellarin reference substance solution (442.80 μ g/ml), descend method to prepare the sample liquid of application of sample in accordance with the law, measure by above-mentioned chromatographic condition according to " preparation of need testing solution " item.The result shows that this law has good average recovery, and average recovery rate is 98.92%, and RSD is 2.72%.The results are shown in Table 9.

Table 9 average recovery test data table

(13) sample size is measured

Get tablet of the present invention (lot number: 031201,031202,031203) each 20, remove coating, accurate claim surely, porphyrize is got the about 0.5g of fine powder, accurate claim fixed, by " preparation of need testing solution " down method prepare in accordance with the law, by above-mentioned chromatographic condition mensuration.Assay the results are shown in Table 10.

Table 10 three batch sample assay result of the tests

Three batch sample average contents are the 1.97mg/ sheet, and the mean transferred rate of scutellarin is 77%.According to average content, and consider floating of crude drug content, therefore sample average content is floated downward 30%, promptly every contains scutellarin 1.38mg as content limit.So the finished product content limit is defined as: every of this product contains Herba Scutellariae Barbatae with scutellarin (C ₂₁H ₁₈O ₁₂) calculate, should be less than 1.38mg.

Experimental example 10: the influence that tablet of the present invention changes rat body weight

Each treated animal body weight change the results are shown in Figure 1.

Experimental example 11: the influence that tablet of the present invention changes the rat uterus histopathology

HE dyeing shows that normal rats uterine smooth muscle cell is elongated, marshalling, and nucleus is spindle shape or shaft-like.The a large amount of hypertrophy of model group rat endometrium body of gland, myometrium thickens, and multiple, focal hypertrophy occurs, and the crisscross boundary of muscle fiber is unclear, and nuclear comparatively dense hypertrophy is active phenomena, is full of juice in the cavity of uterus, and body of uterus enlarges markedly.Model group rat uterus smooth muscle layer pathological change and people's hysteromyoma pathology histological structure are similar.But do not see around the focal hypertrophy agglomerate that tangible peplos forms.Mifepristone and tablet 15g crude drug of the present invention/kg dosage treated animal intra-uterine membranous layer glandular hyperplasia degree, the outgrowth phenomenon of myometrium and body of uterus increase etc. change less than model group.

Experimental example 12: tablet of the present invention is to the influence of the every uterus of rat index

Model group rat uterus weight, uterus coefficient, uterus length, cervix uteri and branch bight, uterus maximum gauge obviously increase than normal group.Tablet 15g crude drug/kg of the present invention, 7.5g crude drug/kg and 3.75g crude drug/kg dosage group rat uterus weight, uterus coefficient, uterus length, cervix uteri and branch bight, uterus maximum gauge are starkly lower than model group.See Table 11.

Table 11. tablet of the present invention is to the influence of the every uterus of rat index

△: compare P＜0.05, *: compare P＜0.05 with normal group with model group

Experimental example 13: tablet of the present invention is female to rat periphery serum, the influence of progesterone level

Model group and normal group compare, model group serum E ₂, the P value all obviously raises.Each medication group and model group compare, mifepristone group E ₂, the P level all obviously descends.Progesterone level and model group rat more all have decline in various degree in the tablet in treatment group rat blood serum of the present invention, and wherein 15g crude drug/kg dosage group has significant difference (P＜0.05) with it.See Table 12.

Table 12. tablet of the present invention is female to rat blood serum, the influence of progesterone level

△: compare P＜0.05, *: compare P＜0.05 with normal group with model group

Experimental example 14: the influence that tablet of the present invention is female to the rat uterus smooth muscle, progesterone receptor (ER, PR) is expressed

Immunohistochemical staining shows that the positive expression rate of model group rat uterus smooth muscle cell ER and PR is apparently higher than normal rat.Tablet of the present invention and mifepristone group and model group compare, and smooth muscle cell ER and PR positive expression significantly descend, and wherein the decline of mifepristone group and tablet high dose group of the present invention is the most obvious, and with normal group notable difference are arranged relatively.See Table 13.

Table 13. tablet of the present invention is to experimental hysteromyoma rat uterus

The influence of smooth muscle ER, PR positive expression rate

△: compare P＜0.05, *: compare P＜0.05 with normal group with model group

Experimental example 15: tablet of the present invention is to the influence of Cavia porcellus body weight change

Each treated animal body weight change is seen Fig. 2.

Experimental example 16: the influence that tablet of the present invention changes Cavia porcellus uterus histopathology

HE dyeing shows that normal group Cavia porcellus uterine smooth muscle cell is elongated, marshalling, and nucleus is spindle shape or shaft-like.Model group Cavia porcellus subangle uterus root smooth muscle layer obviously is inhomogeneous thickening, and the smooth muscle cell arrangement disorder, and smooth muscle is arranged and is cirriform or braiding shape; pathological changes is similar to tumor sample hypertrophy; a large amount of hypertrophy of endometrial gland, is full of juice in the cavity of uterus, and body of uterus enlarges markedly.Model group Cavia porcellus uterine smooth muscle layer pathological change and people's hysteromyoma pathology histological structure are similar.Mifepristone and tablet 15g crude drug of the present invention/kg dosage treated animal intra-uterine membranous layer glandular hyperplasia degree, the outgrowth phenomenon of myometrium and body of uterus increase etc. change less than model group.

Experimental example 17: tablet of the present invention is to the influence of the every uterus of Cavia porcellus index

Model group Cavia porcellus uterus weight, uterus coefficient, uterus length cervix uteri and branch bight, uterus maximum gauge obviously increase than normal group.Tablet 15g crude drug/kg of the present invention and 7.5g crude drug/kg dosage group Cavia porcellus uterus weight, uterus coefficient are starkly lower than model group.See Table 14.

Table 14. tablet of the present invention is to the influence of the every uterus of Cavia porcellus index

△: compare P＜0.05, *: compare P＜0.05 with normal group with model group

Experimental example 18: tablet of the present invention is female to Cavia porcellus periphery serum, the influence of progesterone level

Model group and normal group compare, model group serum E ₂, the P value all obviously raises.Compare mifepristone group serum E with model group ₂, the P level all obviously descends.E in the tablet in treatment group guinea pig serum of the present invention ₂, P level and model group Cavia porcellus more all have decline in various degree, wherein 15g crude drug/kg dosage group has significant difference (P＜0.05) with it.See Table 15.

Table 15. tablet of the present invention is female to guinea pig serum, the influence of progesterone level

△: compare P＜0.05, *: compare P＜0.05 with normal group with model group

Experimental example 19: the influence that tablet of the present invention is female to the Cavia porcellus uterine smooth muscle, progesterone receptor (ER, PR) is expressed

Immunohistochemical staining shows that the positive expression rate of model group Cavia porcellus uterine smooth muscle cell ER and PR is apparently higher than normal guinea pig.Tablet of the present invention and mifepristone group and model group compare, and smooth muscle cell ER and PR positive expression significantly descend, and wherein mifepristone group and tablet high dose group of the present invention descend the most obvious.See Table 16.

Table 16. tablet of the present invention is to experimental hysteromyoma Cavia porcellus uterus

The influence of smooth muscle ER, PR positive expression rate

△: compare P＜0.05, *: compare P＜0.05 with normal group with model group

Description of drawings:

Each treated animal body weight change result of Fig. 1

Each treated animal body weight change of Fig. 2

Following embodiment all can realize the effect of above-mentioned experimental example.

Embodiment 1:Tablet of the present invention

Get Carapax Trionycis (processed with vinegar) 750g, Fructus Polygoni Orientalis 750g, rhizoma sparganic 500g; Add conventional adjuvant, technology is prepared into tablet routinely.

Usage and dosage: oral, each 4, every day three times.

Embodiment 2:Capsule of the present invention

Get Carapax Trionycis 700g, Fructus Polygoni Orientalis 850g, rhizoma sparganic 450g; Add conventional adjuvant, technology is prepared into capsule routinely.

Usage and dosage: oral, each 8, every day three times.

Embodiment 3:Granule of the present invention

Get Carapax Trionycis 850g, Fructus Polygoni Orientalis 700g, rhizoma sparganic 550g; Add conventional adjuvant, technology is prepared into granule routinely.

Usage and dosage: boiled water is taken after mixing it with water, and each 1 bag 1, every day three times.

Embodiment 4:Tablet of the present invention

1, prescription

Carapax Trionycis 750g Fructus Polygoni Orientalis 750g rhizoma sparganic 500g

Herba Scutellariae Barbatae 750g Semen Coicis 750g Radix Notoginseng 300g

Make 1000;

2, method for making

(1) pretreatment: Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination.

(2) alcohol extraction: Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 10 times of amount 70% ethanol, reflux, extract, three times, and each 1.5 hours, extracting solution merged, leave standstill, filter, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol, being concentrated into relative density is the clear paste I of 1.25～1.30 (60 ℃)

(3) water is carried: Carapax Trionycis decocts with water 1 hour, adds the alcohol extraction medicinal residues again, adds the water of 12 times of amounts, decoct three times, and each 1.5 hours, merge the water extract, leave standstill, filter, filtrate decompression is concentrated into the clear paste II that relative density is 1.25～1.30 (60 ℃), and is standby.

(4) pulverize: Radix Notoginseng powder is broken into 80 purpose coarse powder, then the coarse powder micronizing is become the micropowder of particle diameter≤20 μ m, standby.

(5) mixing, drying: with clear paste I, clear paste II and Radix Notoginseng micropowder mix homogeneously, put vacuum drying oven drying (≤80 ℃), it is standby to get dry extract.

(6) pulverize, granulate: dried cream powder is broken, cross 100 mesh sieves, adding weight ratio is the lactose of 15-30%, with the weight ratio is that 8-12%, concentration are that 15% poly-iodine ketone k30 alcoholic solution is made soft material, 14 order stainless steel meshs are granulated, dry (≤60 ℃), 14 order stainless steel mesh granulate, add 3% cross-linking sodium carboxymethyl cellulose and 0.5% magnesium stearate, mix homogeneously.

(7) tabletting: sheet heavily is 0.87g.

(8) coating: with Opadry thin film coating material coating, coating is to the heavy 0.90g of sheet.

(9) packing: plastic bottle packing is distributed into 60 slices/bottle, promptly.

Usage and dosage: oral, each 4, every day three times.

Embodiment 5:Tablet of the present invention

Carapax Trionycis (processed with vinegar) 700g, Fructus Polygoni Orientalis 850g, rhizoma sparganic 450g, Herba Scutellariae Barbatae 850g, Semen Coicis 700g, Radix Notoginseng micropowder 320g make 1000;

Take by weighing the above-mentioned raw materials medicine, take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 10 times of amount 70% ethanol, reflux, extract, three times, and each 1.5 hours, extracting solution merged, leave standstill, filter, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis (processed with vinegar) decocts with water 1 hour, adds the alcohol extraction medicinal residues again, adds the water of 12 times of amounts, decocts three times, and each 1.5 hours, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, the mensuration temperature is 60 ℃;

Directly get the Radix Notoginseng micropowder, standby;

Dried cream powder is broken, cross 100 mesh sieves, the adding weight ratio is 20% lactose, with weight ratio be 10%, concentration is that 15% poly-iodine ketone k30 alcoholic solution is made soft material in right amount, granulates drying, granulate adds 3% cross-linking sodium carboxymethyl cellulose and 0.5% magnesium stearate, mix homogeneously; Tabletting promptly gets tablet of the present invention.

Usage and dosage: oral, each 4, every day three times.

Embodiment 6: capsule of the present invention

Carapax Trionycis (processed with vinegar) 750g, Fructus Polygoni Orientalis 750g, rhizoma sparganic 500g, Herba Scutellariae Barbatae 750g, Semen Coicis 750g, Radix Notoginseng 300g.

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 6 times of amount 90% ethanol, reflux, extract, 1 time, and each 2 hours, extracting solution merged, leave standstill, filter, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis or Carapax Trionycis (processed with vinegar) decoct with water 1 hour, add the alcohol extraction medicinal residues again, add the water of 8 times of amounts, decoct 3 times, each 0.5 hour, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

Radix Notoginseng powder is broken into 80 purpose coarse powder, then the coarse powder micronizing is become the micropowder of particle diameter≤20 μ m, standby;

With clear paste I, clear paste II and Radix Notoginseng micropowder mix homogeneously, put vacuum drying oven drying (≤80 ℃), get dry extract, standby;

Get dried cream, adding weight ratio is 20% lactose, with weight ratio be 10%, concentration is that 15% poly-iodine ketone k30 alcoholic solution is made soft material, granulate, dry, granulate adds 3% cross-linking sodium carboxymethyl cellulose and 0.5% magnesium stearate, mix homogeneously, fill, loading amount 0.45g is prepared into capsule, promptly gets capsule of the present invention.

Usage and dosage: oral, each 8, every day three times.

Embodiment 7:Granule of the present invention

Carapax Trionycis 700g, Fructus Polygoni Orientalis 850g, rhizoma sparganic 450g, Herba Scutellariae Barbatae 850g, Semen Coicis 700g, Radix Notoginseng micropowder 320g.

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 10 times of amount 70% ethanol, reflux, extract, 3 times, and each 1 hour, extracting solution merged, leave standstill, filter, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis or Carapax Trionycis (processed with vinegar) decoct with water 1 hour, add the alcohol extraction medicinal residues again, add the water of 12 times of amounts, decoct 1 time, each 1.5 hours, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

Clear paste I, clear paste II and Radix Notoginseng micropowder are mixed, add conventional adjuvant dextrin, Icing Sugar, starch, sweet foline etc., mix homogeneously is granulated, and puts the vacuum drying oven drying, and temperature is not higher than 80 ℃, granulate, and every bag of 10g of packing is prepared into granule.Promptly get granule of the present invention.

Usage and dosage: each 1 bag, every day three times, boiled water is taken after mixing it with water.

Embodiment 8:Pill of the present invention

Carapax Trionycis 850g, Fructus Polygoni Orientalis 700g, rhizoma sparganic 550g, Herba Scutellariae Barbatae 700g, Semen Coicis 850g, Radix Notoginseng 280g.

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 8 times of amount 80% ethanol, reflux, extract, 2 times, and each 1.5 hours, extracting solution merged, leave standstill, filter, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis or Carapax Trionycis (processed with vinegar) decoct with water 1 hour, add the alcohol extraction medicinal residues again, add the water of 10 times of amounts, decoct 2 times, each 1 hour, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

With clear paste I, clear paste II mix homogeneously, dilute with water is standby.

Get Radix Notoginseng micropowder and mix homogeneously such as 15-30% dextrin, starch, put in the coating pan, add above-mentioned clear paste aqueous solution, general ball, limit edged drying is until adding.Dry.Be prepared into pill.

Usage and dosage: oral, each 3.6g, every day three times.

Embodiment 9:The method of quality control of tablet of the present invention

Differentiate: A. gets tablet 1g of the present invention, and porphyrize adds 10 in water, stir evenly water-saturated n-butanol solution 10ml in addition again, close plug, about 10 minutes of jolting was placed 2 hours, and is centrifugal, get supernatant, add 3 times of saturated aqueous solutions of amount n-butyl alcohol, shake up, placement makes layering, gets n-butyl alcohol liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets Radix Notoginseng control medicinal material 0.5g, shines medical material solution in pairs with legal system; It is an amount of to get the arasaponin R1 reference substance again, adds methanol and makes the reference substance solution that every 1ml contains 0.5mg; Test according to thin layer chromatography (appendix IV B), draw each 1 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with ratio is 15: 40: 22: lower floor's solution that chloroform-ethyl acetate of 10-methanol-water is placed below 10 ℃ is developing solvent, launch, take out, dry, spray is with ethanol solution of sulfuric acid (1 → 10), and it is clear to be heated to the speckle colour developing in 105 ℃; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance chromatograph on, show the speckle of same color;

B. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Semen Coicis control medicinal material 0.5g, gets control medicinal material solution with legal system; Test according to thin layer chromatography (appendix IV B), draw each 1 μ l of above-mentioned two kinds of solution, putting respectively on same silica gel g thin-layer plate, is that 30-60 ℃ of petroleum ether-ether-glacial acetic acid of 9: 1: 0.5 is developing solvent with ratio, launches, take out, dry, put under the 365nm uviol lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;

C. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Herba Scutellariae Barbatae control medicinal material 0.5g, gets control medicinal material solution with legal system; It is an amount of to get the scutellarin reference substance again, adds methanol and makes the reference substance solution that every 1ml contains 1mg; Test according to thin layer chromatography (appendix IV B), draw each 5 μ l of above-mentioned solution, putting in the same carboxymethylcellulose sodium solution that contains 4% sodium acetate respectively is on the silica gel g thin-layer plate of adhesive, with ratio is 5: 3: 1: ethyl acetate-butanone of 1-formic acid-water is developing solvent, presaturation 20 minutes launches, and takes out, dry, spray is with 5% ferric chloride alcoholic solution; With the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance on, show identical dirty-green speckle;

Chromatographic condition and system suitability are filler with octadecylsilane chemically bonded silica; With ratio is that methanol-water-acetic acid of 35: 61: 4 is mobile phase; The detection wavelength is 335nm; Number of theoretical plate calculates by the scutellarin peak should be not less than 3000;

The preparation of need testing solution: get 20 of this films, remove coating, the accurate title, decided porphyrize, get 0.5g, the accurate title, decide, and puts in the tool plug conical flask, the accurate methanol 25ml that adds, close plug claims to decide weight, supersound process (power 300W, frequency 33kHz) 30 minutes is put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, get subsequent filtrate, promptly;

Every of this product contains Herba Scutellariae Barbatae with scutellarin (C ₂₁H ₁₈O ₁₂) calculate, must not be less than 1.38mg.

Claims

1, a kind of pharmaceutical composition for the treatment of hysteromyoma is characterized in that this pharmaceutical composition made by following bulk drugs:

Carapax Trionycis 600-900 weight parts water Fructus Carthami tinctorii 600-900 weight portion

Rhizoma sparganic 400-600 weight portion Herba Scutellariae Barbatae 600-900 weight portion

Semen Coicis 600-900 weight portion Radix Notoginseng 250-350 weight portion.

2, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following bulk drugs:

Carapax Trionycis 750 weight parts water Fructus Carthami tinctoriis 750 weight portion rhizoma sparganic 500 weight portions

Herba Scutellariae Barbatae 750 weight portion Semen Coiciss 750 weight portion Radix Notoginseng 300 weight portions.

3, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following bulk drugs:

Carapax Trionycis 700 weight parts water Fructus Carthami tinctoriis 850 weight portion rhizoma sparganic 450 weight portions

Herba Scutellariae Barbatae 850 weight portion Semen Coiciss 700 weight portion Radix Notoginseng 320 weight portions.

4, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following bulk drugs:

Carapax Trionycis 850 weight parts water Fructus Carthami tinctoriis 700 weight portions, rhizoma sparganic 550 weight portions

Herba Scutellariae Barbatae 700 weight portion Semen Coiciss 850 weight portions, Radix Notoginseng 280 weight portions.

5, as described any one pharmaceutical composition of claim 1-4, it is characterized in that Carapax Trionycis is a Carapax Trionycis (processed with vinegar) in this pharmaceutical composition crude drug, Radix Notoginseng is the micropowder of Radix Notoginseng.

6, as described any one pharmaceutical composition of claim 1-4, it is characterized in that getting pharmaceutical composition crude drug of the present invention, press the pharmaceutics common process, add conventional adjuvant, be prepared into clinical acceptable: decoction, tablet, pill, powder, granule, oral liquid, injection, capsule or suspensoid.

7, pharmaceutical composition as claimed in claim 5, it is characterized in that getting pharmaceutical composition crude drug of the present invention, press the pharmaceutics common process, add conventional adjuvant, be prepared into clinical acceptable: decoction, tablet, pill, powder, granule, oral liquid, injection, capsule or suspensoid.

8, preparation of drug combination method as claimed in claim 6 is characterized in that this method is:

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 6-10 and doubly measure 70%-90% ethanol, reflux, extract, 1-3 time, each 1-2 hour, extracting solution merges, and leaves standstill, and filters, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis decocts with water 1 hour, adds the alcohol extraction medicinal residues again, adds the water that 8-12 doubly measures, and decocts 1-3 time, each 0.5-1.5 hour, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

Radix Notoginseng powder is broken into 80 purpose coarse powder, then the coarse powder superfine powder is broken into micropowder, standby;

Get pharmaceutical composition extract of the present invention, add conventional adjuvant,, be prepared into clinical acceptable tablet, capsule, pill or granule according to the pharmaceutics common process.

9, preparation of drug combination method as claimed in claim 7 is characterized in that this method is:

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 6-10 and doubly measure 70%-90% ethanol, reflux, extract, 1-3 time, each 1-2 hour, extracting solution merges, and leaves standstill, and filters, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis (processed with vinegar) decocts with water 1 hour, adds the alcohol extraction medicinal residues again, adds the water that 8-12 doubly measures, and decocts 1-3 time, each 0.5-1.5 hour, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

Directly get the Radix Notoginseng micropowder, standby;

10, preparation of drug combination method as claimed in claim 8 or 9 is characterized in that in the preparation of pharmaceutical compositions method of the present invention that the Radix Notoginseng micropowder is the micropowder of particle diameter≤20 μ m or the micropowder that Radix Notoginseng coarse powder micronizing is become particle diameter≤20 μ m.

11, preparation of drug combination method as claimed in claim 8 or 9 is characterized in that this method is:

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis or Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 10 times of amount 70% ethanol, reflux, extract, three times, and each 1.5 hours, extracting solution merged, leave standstill, filter, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25～1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis or Carapax Trionycis (processed with vinegar) decoct with water 1 hour, add the alcohol extraction medicinal residues again, add the water of 12 times of amounts, decoct three times, each 1.5 hours, merge the water extract, leave standstill, filter, it is 1.25～1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

12, preparation of drug combination method as claimed in claim 11 is characterized in that in the preparation of pharmaceutical compositions method of the present invention, and the Radix Notoginseng micropowder is the micropowder of particle diameter≤20 μ m or the micropowder that Radix Notoginseng coarse powder micronizing is become particle diameter≤20 μ m.

13, as preparation of drug combination method as described in claim 8 or 9, it is characterized in that this pharmaceutical composition adds adjuvant as follows and is prepared into tablet:

Take by weighing the above-mentioned raw materials medicine, Fructus Polygoni Orientalis is ground into coarse granule, Carapax Trionycis or Carapax Trionycis (processed with vinegar), rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis, Radix Notoginseng, inspection decontamination; Fructus Polygoni Orientalis, rhizoma sparganic, Herba Scutellariae Barbatae, Semen Coicis add 6-10 and doubly measure 70%-90% ethanol, reflux, extract, 1-3 time, each 1-2 hour, extracting solution merges, and leaves standstill, and filters, the alcohol extraction medicinal residues are standby, decompression filtrate recycling ethanol is concentrated into relative density and is 1.25 ~ 1.30 clear paste I, and measuring temperature is 60 ℃;

Carapax Trionycis or Carapax Trionycis (processed with vinegar) decoct with water 1 hour, add the alcohol extraction medicinal residues again, add the water that 8-12 doubly measures, and decoct 1-3 time, each 0.5-1.5 hour, merge the water extract, leave standstill, filter, it is 1.25 ~ 1.30 clear paste II that filtrate decompression is concentrated into relative density, standby, and measuring temperature is 60 ℃;

Dried cream powder is broken, sieve, adding weight ratio is the 15-30% lactose, with the weight ratio is that 8-12%, concentration are that the poly-iodine ketone K30 alcoholic solution of 5-15% is made soft material, granulates drying, granulate adds 1-3% cross-linking sodium carboxymethyl cellulose and 0.5-1% magnesium stearate, mix homogeneously; Tabletting, sheet heavily are 0.87g; With Opadry thin film coating material coating, coating is to the heavy 0.90g of sheet; Plastic bottle packing is distributed into 60 slices/bottle, promptly.

14, as preparation of drug combination method as described in the claim 13, it is characterized in that this pharmaceutical composition adds adjuvant as follows and is prepared into tablet:

Dried cream powder is broken, sieve, add weight ratio and be 20% lactose, with weight ratio be 10%, concentration is that 15% poly-iodine ketone K30 alcoholic solution is made soft material, granulate, drying, granulate adds 3% cross-linking sodium carboxymethyl cellulose and 0.5% magnesium stearate, mix homogeneously; Tabletting, sheet heavily are 0.87g; With Opadry thin film coating material coating, coating is to the heavy 0.90g of sheet; Plastic bottle packing is distributed into 60 slices/bottle, promptly.

15, as preparation of drug combination method as described in the claim 13, it is characterized in that the Radix Notoginseng micropowder is the micropowder of particle diameter≤20 μ m or the micropowder that Radix Notoginseng coarse powder micronizing becomes particle diameter≤20 μ m in this pharmaceutical composition method for preparing tablet thereof; Soft material is granulated and granulate with 14 order stainless steel meshs, and baking temperature is not higher than 60 ℃.

16, as preparation of drug combination method as described in the claim 14, it is characterized in that the Radix Notoginseng micropowder is the micropowder of particle diameter≤20 μ m or the micropowder that Radix Notoginseng coarse powder micronizing becomes particle diameter≤20 μ m in this pharmaceutical composition method for preparing tablet thereof; Soft material is granulated and granulate with 14 order stainless steel meshs, and baking temperature is not higher than 60 ℃.

17, the detection method of pharmaceutical composition tablet as claimed in claim 7 is characterized in that discriminating in this detection method comprises one or more in the following method:

A. get tablet 1g of the present invention, porphyrize adds 10 in water, stir evenly water-saturated n-butanol solution 10ml in addition again, close plug, about 10 minutes of jolting was placed 2 hours, and is centrifugal, get supernatant, add 3 times of saturated aqueous solutions of amount n-butyl alcohol, shake up, placement makes layering, gets n-butyl alcohol liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets Radix Notoginseng control medicinal material 0.5g, shines medical material solution in pairs with legal system; Get the arasaponin R1 reference substance again, add methanol and make the reference substance solution that every 1ml contains 0.5mg; Test according to thin layer chromatography, draw each 1 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, be that lower floor's solution that chloroform-ethyl acetate-methanol-water of 12-18: 32-48: 18-26: 8-12 is placed below 10 ℃ is developing solvent with the ratio, launch, take out, dry, spray to be being diluted to 1ml the ethanol solution of sulfuric acid of 10ml, and it is clear to be heated to the speckle colour developing in 105 ℃; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance chromatograph on, show the speckle of same color;

B. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Semen Coicis control medicinal material 0.5g, gets control medicinal material solution with legal system; Test according to thin layer chromatography, draw each 1 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be 8-10: 1-2 with the ratio: 0.5 30-60 ℃ petroleum ether-ether-glacial acetic acid is developing solvent, launches, take out, dry, put under the 365nm uviol lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;

C. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Herba Scutellariae Barbatae control medicinal material 0.5g, gets control medicinal material solution with legal system; Get the scutellarin reference substance again, add methanol and make the reference substance solution that every 1ml contains 1mg; Test according to thin layer chromatography, draw each 5 μ l of above-mentioned solution, putting in the same carboxymethylcellulose sodium solution that contains 4% sodium acetate respectively is on the silica gel g thin-layer plate of adhesive, ethyl acetate-butanone-formic acid-the water that with the ratio is 4-6: 2-4: 1-2: 1-2 is developing solvent, presaturation 20 minutes launches, and takes out, dry, spray is with 5% ferric chloride alcoholic solution; With the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance on, show identical dirty-green speckle.

18, the detection method of pharmaceutical composition tablet as claimed in claim 17 is characterized in that discriminating in this detection method comprises one or more in the following method:

A. get tablet 1g of the present invention, porphyrize adds 10 in water, stir evenly water-saturated n-butanol solution 10ml in addition again, close plug, about 10 minutes of jolting was placed 2 hours, and is centrifugal, get supernatant, add 3 times of saturated aqueous solutions of amount n-butyl alcohol, shake up, placement makes layering, gets n-butyl alcohol liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets Radix Notoginseng control medicinal material 0.5g, shines medical material solution in pairs with legal system; Get the arasaponin R1 reference substance again, add methanol and make the reference substance solution that every 1ml contains 0.5mg; Test according to thin layer chromatography, draw each 1 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with ratio is 15: 40: 22: lower floor's solution that chloroform-ethyl acetate of 10-methanol-water is placed below 10 ℃ is developing solvent, launch, take out, dry, spray to be being diluted to 1ml the ethanol solution of sulfuric acid of 10ml, and it is clear to be heated to the speckle colour developing in 105 ℃; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance chromatograph on, show the speckle of same color;

B. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Semen Coicis control medicinal material 0.5g, gets control medicinal material solution with legal system; Test according to thin layer chromatography, draw each 1 μ l of above-mentioned two kinds of solution, putting respectively on same silica gel g thin-layer plate, is that 30-60 ℃ of petroleum ether-ether-glacial acetic acid of 9: 1: 0.5 is developing solvent with ratio, launches, take out, dry, put under the 365nm uviol lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;

C. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Herba Scutellariae Barbatae control medicinal material 0.5g, gets control medicinal material solution with legal system; Get the scutellarin reference substance again, add methanol and make the reference substance solution that every 1ml contains 1mg; Test according to thin layer chromatography, draw each 5 μ l of above-mentioned solution, putting in the same carboxymethylcellulose sodium solution that contains 4% sodium acetate respectively is on the silica gel g thin-layer plate of adhesive, with ratio is 6: 3: 1: ethyl acetate-butanone of 1-formic acid-water is developing solvent, presaturation 20 minutes launches, and takes out, dry, spray is with 5% ferric chloride alcoholic solution; With the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance on, show identical dirty-green speckle.

19,, it is characterized in that this detection method also comprises following content assaying method as the detection method of claim 17 or 18 described pharmaceutical composition tablets:

According to high effective liquid chromatography for measuring;

The preparation of reference substance solution: get the scutellarin reference substance, it is fixed to claim, adds methanol and makes the reference substance solution that every 1ml contains 80 μ g;

The preparation of need testing solution: get 20 of this films, remove coating, it is fixed to claim, porphyrize, get 0.5g, it is fixed to claim, puts in the tool plug conical flask, add methanol 25ml, close plug claims to decide weight, supersound process 30 minutes, ultrasonic power are that 300W, supersonic frequency are 33kHz, put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, get subsequent filtrate, promptly;

Algoscopy: draw each 5ul of reference substance solution and need testing solution respectively, inject chromatograph of liquid, measure, promptly;

Every in tablet of the present invention contains Herba Scutellariae Barbatae and calculates with scutellarin, must not be less than 1.38mg.

20, the detection method of pharmaceutical composition tablet as claimed in claim 19 is characterized in that this detection method also comprises following content assaying method:

According to high effective liquid chromatography for measuring;

The preparation of reference substance solution: get the scutellarin reference substance, the accurate title, decide, and adds methanol and make the reference substance solution that every 1ml contains 80 μ g;

The preparation of need testing solution: get 20 of this films, remove coating, it is fixed to claim, porphyrize, get 0.5g, the accurate title, decide, and puts in the tool plug conical flask, add methanol 25ml, close plug claims to decide weight, supersound process 30 minutes, ultrasonic power are that 300W, supersonic frequency are 33kHz, put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, get subsequent filtrate, promptly;

21, the detection method of pharmaceutical composition tablet as claimed in claim 6 is characterized in that this detection method is:

Differentiate: A. gets tablet 1g of the present invention, and porphyrize adds 10 in water, stir evenly water-saturated n-butanol solution 10ml in addition again, close plug, about 10 minutes of jolting was placed 2 hours, and is centrifugal, get supernatant, add 3 times of saturated aqueous solutions of amount n-butyl alcohol, shake up, placement makes layering, gets n-butyl alcohol liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets Radix Notoginseng control medicinal material 0.5g, shines medical material solution in pairs with legal system; Get the arasaponin R1 reference substance again, add methanol and make the reference substance solution that every 1ml contains 0.5mg; According to thin layer chromatography (test, draw each 1 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with ratio is 15: 40: 22: lower floor's solution that chloroform-ethyl acetate of 10-methanol-water is placed below 10 ℃ is developing solvent, launch, take out, dry, spray to be being diluted to 1ml the ethanol solution of sulfuric acid of 10ml, and it is clear to be heated to the speckle colour developing in 105 ℃; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance chromatograph on, show the speckle of same color;

C. get tablet 1g of the present invention, porphyrize adds ethanol 10ml, and supersound extraction 30 minutes filters, and the filtrate evaporate to dryness adds methanol 1ml and makes dissolving, as need testing solution; Other gets Herba Scutellariae Barbatae control medicinal material 0.5g, gets control medicinal material solution with legal system; Get the scutellarin reference substance again, add methanol and make the reference substance solution that every 1ml contains 1mg; Test according to thin layer chromatography, draw each 5 μ l of above-mentioned solution, putting in the same carboxymethylcellulose sodium solution that contains 4% sodium acetate respectively is on the silica gel g thin-layer plate of adhesive, with ratio is 6: 3: 1: ethyl acetate-butanone of 1-formic acid-water is developing solvent, presaturation 20 minutes launches, and takes out, dry, spray is with 5% ferric chloride alcoholic solution; With the corresponding position of control medicinal material chromatograph on, show the speckle of same color; With the corresponding position of reference substance on, show identical dirty-green speckle;

Assay: according to high effective liquid chromatography for measuring;

The preparation of need testing solution: get 20 of this films, remove coating, the accurate title, decided porphyrize, get 0.5g, the accurate title, decide, and puts in the tool plug conical flask, add methanol 25ml, close plug claims to decide weight, supersound process 30 minutes, ultrasonic power are that 300W, supersonic frequency are 33kHz, put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with methanol, filter, get subsequent filtrate, promptly;

22, as claim 1,2, the application of 3 or 4 described pharmaceutical compositions in preparation treatment hysteromyoma medicine.

23, the application of pharmaceutical composition as claimed in claim 5 in preparation treatment hysteromyoma medicine.

24, application as claimed in claim 22, it is characterized in that described treatment hysteromyoma be meant suppress that the hysteromyoma smooth muscle cell is female, progesterone receptor positive expression or reduce female, progesterone level in the serum.

25, application as claimed in claim 23, it is characterized in that described treatment hysteromyoma be meant suppress that the hysteromyoma smooth muscle cell is female, progesterone receptor positive expression or reduce female, progesterone level in the serum.